Does the media prefer RXRX or TECX?

In the previous week, Recursion Pharmaceuticals had 10 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 2 mentions for Tectonic Therapeutic. Recursion Pharmaceuticals' average media sentiment score of 0.82 beat Tectonic Therapeutic's score of 0.62 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, HCM or TECX?

HUTCHMED has higher revenue and earnings than Tectonic Therapeutic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.49 $456.91M N/A N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is HCM or TECX more profitable?

HUTCHMED's return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Tectonic Therapeutic N/A -32.33% -30.92%

Does the media refer more to HCM or TECX?

In the previous week, HUTCHMED had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 5 mentions for HUTCHMED and 2 mentions for Tectonic Therapeutic. HUTCHMED's average media sentiment score of 0.76 beat Tectonic Therapeutic's score of 0.62 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECX or BHC?

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 2 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.62 beat Bausch Health Cos' score of 0.49 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, TRVI or TECX?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is TRVI or TECX more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Tectonic Therapeutic N/A -32.33% -30.92%

Does the media favor TECX or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.62 beat AbCellera Biologics' score of 0.55 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Tectonic Therapeutic (TECX) Competitors

$30.28 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$30.32 +0.04 (+0.13%)

As of 06/12/2026 06:38 PM Eastern

Compare

TECX vs. RXRX, HCM, BHC, TRVI, and ABCL

Should you buy Tectonic Therapeutic stock or one of its competitors? MarketBeat compares Tectonic Therapeutic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tectonic Therapeutic include Recursion Pharmaceuticals (RXRX), HUTCHMED (HCM), Bausch Health Cos (BHC), Trevi Therapeutics (TRVI), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.

How does Tectonic Therapeutic compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, suggesting that its stock price is 219% more volatile than the broader market.

Tectonic Therapeutic has lower revenue, but higher earnings than Recursion Pharmaceuticals. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	22.35	-$644.76M	-$1.20	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Recursion Pharmaceuticals currently has a consensus target price of $8.10, suggesting a potential upside of 157.14%. Tectonic Therapeutic has a consensus target price of $79.40, suggesting a potential upside of 162.22%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Recursion Pharmaceuticals had 10 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 2 mentions for Tectonic Therapeutic. Recursion Pharmaceuticals' average media sentiment score of 0.82 beat Tectonic Therapeutic's score of 0.62 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Tectonic Therapeutic's return on equity of -32.33% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Tectonic Therapeutic beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to HUTCHMED?

HUTCHMED (NASDAQ:HCM) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

HUTCHMED has higher revenue and earnings than Tectonic Therapeutic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.49	$456.91M	N/A	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

In the previous week, HUTCHMED had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 5 mentions for HUTCHMED and 2 mentions for Tectonic Therapeutic. HUTCHMED's average media sentiment score of 0.76 beat Tectonic Therapeutic's score of 0.62 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

HUTCHMED's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-32.33%	-30.92%

HUTCHMED currently has a consensus target price of $16.80, suggesting a potential upside of 53.28%. Tectonic Therapeutic has a consensus target price of $79.40, suggesting a potential upside of 162.22%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

HUTCHMED has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, meaning that its stock price is 219% more volatile than the broader market.

Summary

Tectonic Therapeutic beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Bausch Health Cos?

Tectonic Therapeutic (NASDAQ:TECX) and Bausch Health Cos (NYSE:BHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Bausch Health Cos has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Bausch Health Cos	$10.27B	0.18	$157M	-$3.24	N/A

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 2 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.62 beat Bausch Health Cos' score of 0.49 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tectonic Therapeutic presently has a consensus target price of $79.40, indicating a potential upside of 162.22%. Bausch Health Cos has a consensus target price of $8.00, indicating a potential upside of 58.26%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Tectonic Therapeutic has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Tectonic Therapeutic's return on equity of -32.33% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Tectonic Therapeutic has a beta of 3.19, meaning that its share price is 219% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Tectonic Therapeutic beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.89 beat Tectonic Therapeutic's score of 0.62 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Trevi Therapeutics	Very Positive
Tectonic Therapeutic	Positive

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Trevi Therapeutics' return on equity of -24.53% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Trevi Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, indicating that its stock price is 219% more volatile than the broader market.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Trevi Therapeutics presently has a consensus price target of $22.90, indicating a potential upside of 61.15%. Tectonic Therapeutic has a consensus price target of $79.40, indicating a potential upside of 162.22%. Given Tectonic Therapeutic's higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Trevi Therapeutics beats Tectonic Therapeutic on 7 of the 12 factors compared between the two stocks.

How does Tectonic Therapeutic compare to AbCellera Biologics?

Tectonic Therapeutic (NASDAQ:TECX) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Tectonic Therapeutic has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Tectonic Therapeutic presently has a consensus target price of $79.40, suggesting a potential upside of 162.22%. AbCellera Biologics has a consensus target price of $7.80, suggesting a potential upside of 48.85%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, equities research analysts plainly believe Tectonic Therapeutic is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.19, suggesting that its share price is 219% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

In the previous week, AbCellera Biologics had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for AbCellera Biologics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.62 beat AbCellera Biologics' score of 0.55 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Tectonic Therapeutic has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
AbCellera Biologics	$75.13M	21.30	-$146.41M	-$0.48	N/A

Summary

Tectonic Therapeutic beats AbCellera Biologics on 11 of the 16 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$571.36M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-6.79	19.82	24.21	24.42
Price / Sales	N/A	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.25	8.32	10.66	6.83
Net Income	-$74.15M	$23.94M	$3.57B	$337.67M
7 Day Performance	4.41%	3.53%	0.84%	2.68%
1 Month Performance	1.61%	-2.55%	-0.34%	1.56%
1 Year Performance	38.33%	44.82%	25.40%	30.59%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	3.0745 of 5 stars	$30.28 flat	$79.40 +162.2%	+38.3%	$571.38M	N/A	N/A	120
RXRX Recursion Pharmaceuticals	3.4903 of 5 stars	$3.61 -4.7%	$8.10 +124.4%	-36.0%	$2.01B	$74.68M	N/A	400	Options Volume
HCM HUTCHMED	3.1487 of 5 stars	$11.52 +1.1%	$16.80 +45.8%	-35.1%	$1.99B	$548.51M	N/A	1,796	News Coverage Analyst Revision High Trading Volume
BHC Bausch Health Cos	2.5852 of 5 stars	$5.03 -5.4%	$8.00 +59.2%	-16.0%	$1.98B	$10.27B	N/A	20,300	High Trading Volume
TRVI Trevi Therapeutics	2.8069 of 5 stars	$13.50 -3.2%	$22.90 +69.6%	+133.3%	$1.98B	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. RXRX, HCM, BHC, TRVI, and ABCL

How does Tectonic Therapeutic compare to Recursion Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to HUTCHMED?

Summary

How does Tectonic Therapeutic compare to Bausch Health Cos?

Summary

How does Tectonic Therapeutic compare to Trevi Therapeutics?

Summary

How does Tectonic Therapeutic compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. RXRX, HCM, BHC, TRVI, and ABCL

How does Tectonic Therapeutic compare to Recursion Pharmaceuticals?

Which has more volatility & risk, RXRX or TECX?

Which has stronger valuation and earnings, RXRX or TECX?

Do analysts rate RXRX or TECX?

Does the media prefer RXRX or TECX?

Is RXRX or TECX more profitable?

Do institutionals and insiders hold more shares of RXRX or TECX?

Summary

How does Tectonic Therapeutic compare to HUTCHMED?

Which has better valuation and earnings, HCM or TECX?

Does the media refer more to HCM or TECX?

Do institutionals and insiders hold more shares of HCM or TECX?

Is HCM or TECX more profitable?

Do analysts prefer HCM or TECX?

Which has more risk and volatility, HCM or TECX?

Summary

How does Tectonic Therapeutic compare to Bausch Health Cos?

Which has preferable valuation and earnings, TECX or BHC?

Does the media prefer TECX or BHC?

Do analysts prefer TECX or BHC?

Is TECX or BHC more profitable?

Which has more risk & volatility, TECX or BHC?

Do institutionals & insiders have more ownership in TECX or BHC?

Summary

How does Tectonic Therapeutic compare to Trevi Therapeutics?

Does the media refer more to TRVI or TECX?

Which has preferable earnings and valuation, TRVI or TECX?

Is TRVI or TECX more profitable?

Which has more risk & volatility, TRVI or TECX?

Do institutionals and insiders believe in TRVI or TECX?

Do analysts recommend TRVI or TECX?

Summary

How does Tectonic Therapeutic compare to AbCellera Biologics?

Is TECX or ABCL more profitable?

Do analysts recommend TECX or ABCL?

Do insiders and institutionals have more ownership in TECX or ABCL?

Which has more volatility & risk, TECX or ABCL?

Does the media favor TECX or ABCL?

Which has higher earnings & valuation, TECX or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools